Alcoholic Hepatitis Pipeline Insight, NDA Approvals, and Clinical Trials Analysis | Major Companies – Novartis Pharmaceuticals, Durect, and Others
DelveInsight’s, “Alcoholic Hepatitis Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the Alcoholic Hepatitis pipeline drug profiles, including Alcoholic Hepatitis clinical trials and nonclinical stage products. It also covers the Alcoholic Hepatitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Alcoholic Hepatitis Pipeline Report
- Over 10+ Alcoholic Hepatitis companies are evaluating 10+ Alcoholic Hepatitis pipeline therapies in various stages of development, and their anticipated acceptance in the Alcoholic Hepatitis market would significantly increase market revenue.
- The leading Alcoholic Hepatitis Companies include Novartis Pharmaceuticals, Durect, Intercept Pharmaceuticals, Aldeyra Therapeutics, Surrozen, and others
- Promising Alcoholic Hepatitis Pipeline Therapies include Terlipressin, DUR 928, Canakinumab, and others
- The Alcoholic Hepatitis companies and academics are working to assess challenges and seek opportunities that could influence Alcoholic Hepatitis R&D. The Alcoholic Hepatitis therapies under development are focused on novel approaches to treat/improve Alcoholic Hepatitis.
Request a sample and discover the recent breakthroughs happening in the Alcoholic Hepatitis Pipeline landscape @ Alcoholic Hepatitis Pipeline Outlook Report
Alcoholic Hepatitis Overview
Alcoholic hepatitis is an inflammatory condition of the liver caused by heavy alcohol consumption over an extended period of time. Ongoing alcohol use and binge drinking can both aggravate this condition. Continued drinking can lead to additional health conditions, such as cirrhosis, excessive bleeding, or even liver failure.
Recent Developmental Activities in the Alcoholic Hepatitis Treatment Landscape
- Larsucosterol (DUR-928) is a first-in-class, small molecule, new chemical entity, and anendogenous epigenetic regulator. It is an endogenous sulfated oxysterol and an epigenetic regulator and represents a new class of therapeutics with a unique mechanism of action.
- DURECT is currently conducting a Phase IIb study (AHFIRM), a randomized, double-blind, placebo-controlled trial targeting more than 60 clinical trial sites across the US, Europe, the UK, and Australian in subjects with severe alcohol-associated hepatitis. The primary outcome measured will be the 90-day survival rate for patients treated with larsucosterol compared tothose treated with placebo plus standard of care. Secondary endpoints include 28-day survival, the rate of adverse events, Lille and MELD (prognostic scores), and time in the intensive care unit.
- Canakinumab is a human anti-IL-1β monoclonal antibody developed by Novartis. Its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation inpatients with disorders of autoimmune origin. It is delivered intravenously to the patients. The drug is currently being evaluated in a multicenter, double blind, randomized (1:1), placebocontrolled Phase II trial. The trial will follow patients up for 90 days and will be conducted incenters across the United Kingdom. Twenty-six patients will be recruited to each arm of the trial: total 52 patients. The primary endpoint of the trial is histological improvement of alcoholic hepatitis on liver biopsy after 28 days of treatment compared to baseline.
- Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and company believes that the drug may consequently reverse the adverse effects of the cytokine in patients withalcoholic hepatitis.
For further information, refer to the detailed Alcoholic Hepatitis Drugs Launch, Alcoholic Hepatitis Developmental Activities, and Alcoholic Hepatitis News, click here for Alcoholic Hepatitis Ongoing Clinical Trial Analysis
Alcoholic Hepatitis Emerging Drugs Profile
- DUR-928: Durect
DUR-928 is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication. DURECT is currently conducting a Phase IIb study (AHFIRM) in subjects with severe alcohol-associated hepatitis (also called Alcoholic Hepatitis or AH) to evaluate safety and efficacy of DUR-928 treatment. DUR-928 has been shown to inhibit the activity of DNMTs (DNMT-1, 3a and 3b), inhibiting DNA methylation, and upregulating expression of genes involved in signaling pathways associated with cell death, stress response, and lipid biosynthesis, which may ultimately result in increased cell survival, reduced inflammation, and decreased lipotoxicity.
- Canakinumab: Novartis
Canakinumab is a licensed monoclonal antibody inhibitor of IL-1 and may consequently reverse the adverse effects of the cytokine in patients with this disorder. Therefore, the main objective of the Phase II ISAIAH trial is to explore the potential benefits of the IL-1β antibody, Canakinumab (solution for injection), in the treatment of alcoholic hepatitis.
Alcoholic Hepatitis Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Alcoholic Hepatitis. The companies which have their Alcoholic Hepatitis drug candidates in the most advanced stage, i.e. phase III include, Durect.
Find out more about the Alcoholic Hepatitis Diagnosis and Treatment of patients @ Alcoholic Hepatitis Ongoing Clinical Trials Analysis
Scope of the Alcoholic Hepatitis Pipeline Report
- Coverage- Global
- Alcoholic Hepatitis Companies- Novartis Pharmaceuticals, Durect, Intercept Pharmaceuticals, Aldeyra Therapeutics, Surrozen, and others
- Alcoholic Hepatitis Pipeline Therapies- Terlipressin, DUR 928, Canakinumab, and others.
- Alcoholic Hepatitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Discover more about the list of FDA-approved drugs for Alcoholic Hepatitis @ Alcoholic Hepatitis Treatment Landscape
Table of Content
- Introduction
- Executive Summary
- Alcoholic Hepatitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Alcoholic Hepatitis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug: Company
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- DUR-928: Durect
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- SZN 043: Surrozen
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Alcoholic Hepatitis Key Companies
- Alcoholic Hepatitis Key Products
- Alcoholic Hepatitis- Unmet Needs
- Alcoholic Hepatitis- Market Drivers and Barriers
- Alcoholic Hepatitis- Future Perspectives and Conclusion
- Alcoholic Hepatitis Analyst Views
- Alcoholic Hepatitis Key Companies
- Appendix
For further information on the Alcoholic Hepatitis Pipeline therapeutics, reach out @ Alcoholic Hepatitis Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
